AB InBev PureDraught™ Keg System Wins World Beverage Innovation Award
18.11.2019 17:20:00 EET | Business Wire | Press release
AB InBev and its Global Innovation and Technology Center (GITEC) announced that PureDraught™, a revolutionary one-way polymer keg system, won a World Beverage Innovation Award for “Best Manufacturing/Processing Innovation.” The honor was awarded at the BrauBeviale 2019 trade fair in Nuremberg, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191118005495/en/
PureDraught™ keeps beer fresher up to four times longer than a traditional steel keg and reduces the carbon footprint of shipping beer -- all while offering more versatility and variety for bar and restaurant owners. (Photo: Business Wire)
PureDraught™ keeps beer fresher up to four times longer than a traditional steel keg and reduces the carbon footprint of shipping beer -- all while offering more versatility and variety for bar and restaurant owners.
Using a custom-molded, double-walled, bottle-in-bottle polymer keg, PureDraught allows air or gas to be fed into the outer bottle, which keeps its shape and pushes the beer out of the inner bottle. This innovation prevents any air or dispense gas from touching the beer, allowing the beer to remain fresh for 30 days after being tapped instead of just a week.
In addition, PureDraught comes in 6L, 12L and 18L sizes rather than the standard 30L or larger steel keg size, allowing for more flexibility and less wasted product by bar and restaurant owners. The kegs can be stored and dispensed from upright or on their side on a shelf, making them more versatile.
“We are honored that our research and technological innovation for PureDraught has been recognized by the prestigious World Beverage Innovation Awards,” said Rodrigo Sozo, Vice President of AB InBev GITEC. “This is a validation of the hard work and passion of our team as they set out to develop a transformational innovation for draught beer, including superior quality, less carbon footprint and more variety of beers on tap. We are also excited about how the technology platform creates new consumer experiences for all types of occasions of draught beer consumption.”
There are no additional costs for a bar to use the PureDraught system or the beer in the one-way kegs, and in most markets, the system’s custom keg coupler is provided and connected to a bar’s existing beer and gas lines by AB InBev free of charge.
Currently, PureDraught is in use with AB InBev brands in more than eight countries, including the U.S., Mexico, Brazil, China, Italy, Japan and South Korea as well as additional areas of Europe and Africa, providing the best pour of brands like Stella Artois. For more information, including how to convert your establishment to PureDraught, visit https://puredraught.com/.
About AB InBev GITEC
The Global Innovation and Technology Center (GITEC) at AB InBev is the hub of innovation for the company, working across teams and the company’s more than 500 brands to develop new products, processes and technologies. Driven by a team of more than 120 passionate R&D talents from more than 20 countries, GITEC works to revolutionize packaging, make the brewing process more efficient and sustainable, create breakthroughs in how our beers are delivered and dispensed, and to offer new tasting and consumer experiences.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191118005495/en/
Contact information
Media Contact:
Shawn Malayter
Greenhouse Partners
872-267-2636
smalayter@greenhousepartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 04:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom